Skip to main content

Table 3 Associations between metformin use at hospital admission for AMI and MACE over median follow-up of 343 (IQR 1–1436) days using propensity score analysis

From: Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study

EndpointHazard ratio (95% CI)P value
Primary endpoint
 MACE (composite of cardiovascular mortality, AMI and stroke)1.13 (1.03–1.23)0.006
Components of primary endpoint
 Cardiovascular mortality1.12 (1.00–1.25)0.044
 AMI1.07 (0.95–1.21)0.273
 Stroke1.00 (0.83–1.21)0.977
Secondary endpoints
 All-cause mortality1.02 (0.94–1.11)0.660
 HF hospitalisation1.18 (1.06–1.31)0.002
  1. Adjusted for: age at index AMI, sex, ethnicity, BMI, fasted glucose, HbA1c, smoking status, total serum cholesterol, previous HF, previous stroke, previous TIA, previous AAA, previous angina and if ever prescribed insulin prior to index AMI
  2. AMI acute myocardial infarction, HF heart failure